Accession Number:



Novel Cyclic Lipopeptides for Treating Complicated Wound Infections

Descriptive Note:

Technical Report,21 Sep 2015,20 Sep 2019

Corporate Author:

University of Miami Miller School of Medicine Miami United States

Personal Author(s):

Report Date:


Pagination or Media Count:



The purpose for this grant was to develop a new class of antibacterial agents, cyclic lipopeptides, derived from the fusaricidinLI-F family of naturally occurring antifungal antibiotics for the prevention and treatment of complicated combat-related or trauma-induced wound infections caused by multidrug-resistant MDR pathogens and biofilm formation. Three aims were planned 1 To optimizesynthesize lead cyclic lipopeptides and assess their antimicrobialantibiofilm activity and toxicity in vitro 2 to develop and optimize a cyclic lipopeptide delivery system based on anionic graft copolymer nanoparticles for topical application and 3 to characterizeoptimize, evaluate dosing, efficacy, and toxicitysafety of the combined cyclic lipopeptidepolymer nanocomplexes in several porcine models for infection prevention, biofilm elimination, and wound healing. The modification of the amino acid sequences of lead depsipeptides were designed to disrupt the balance between the charge and hydrophobicity leading to a better separation of antibacterial activity and nonselective toxicity. In vitro and in vivo studies were performed to study antimicrobial and wound healing efficacy.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: